A Fresh Look at argenx (ENXTBR:ARGX) Valuation Following Recent Share Price Momentum

argenx (ENXTBR:ARGX) stock has gained fresh attention from investors recently, and its movement stands out when you look at how it has performed over the past month and past 3 months. The company’s trajectory offers some interesting discussion points for those interested in the biotech sector.

See our latest analysis for argenx.

argenx has captured attention with a 40% 90-day share price return and a strong 48% total shareholder return over the last year, reflecting renewed investor optimism on the heels of breakthroughs and robust sales updates. Momentum seems to be building, positioning the company as an intriguing watch in biotech right now.

If the latest gains piqued your interest, the next smart move is exploring other healthcare leaders on our roster. See who’s making waves with See the full list for free.

With shares up sharply and current valuations hovering just above analyst price targets, the real question is whether argenx stock still holds untapped value or if the market already expects further growth from here.

Most Popular Narrative: 2% Overvalued

With argenx’s last close price now eclipsing the most widely followed narrative’s fair value estimate, investors are watching to see if the current optimism will hold against future results and evolving assumptions.

Strategic collaborations (e.g., with Unnatural Products for AI-driven peptide discovery and regional partners for global commercialization) are increasing operational efficiency, reducing commercial risk, and may boost long-term profitability through margin expansion and accelerated entry into emerging markets.

Read the complete narrative.

What underpins this high-stakes view? The narrative leans on expected blockbuster earnings, aggressive revenue expansion, and ambitious margin targets. Yet it all hinges on bold growth assumptions just out of view. Want to know what’s fueling this fair value? Get the inside story on the projections and critical levers driving the calculation. Read on for the full narrative.

Result: Fair Value of $769.91 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, sustained pressure from a rapidly intensifying competitive landscape and heavy reliance on one primary product could still challenge argenx’s bullish outlook.

Find out about the key risks to this argenx narrative.

Another View: What About the DCF?

While analysts currently see argenx as overvalued based on their price target methods, our SWS DCF model presents a very different outlook. The DCF calculation suggests argenx trades at a steep discount to intrinsic value, pointing toward significant upside potential if those growth forecasts hold true. Which story will the market believe?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out argenx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 906 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own argenx Narrative

If this perspective doesn’t quite match your own insights or you prefer to dive deeper into the figures yourself, crafting a personalized analysis is quick and easy. Just take a few minutes, set your assumptions, and see what story emerges. Do it your way

A great starting point for your argenx research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Expand your portfolio with real opportunities by targeting trends before the crowd. Don’t let another breakthrough stock pass you by. See what’s catching smart investors’ interest right now.

• Grow your wealth with income by tapping into these 18 dividend stocks with yields > 3% that deliver attractive yields and steady payout histories.
• Spot tomorrow’s tech disruptors among these 27 AI penny stocks taking artificial intelligence to practical, profitable new heights.
• Capitalize on undervalued opportunities missed by others using these 906 undervalued stocks based on cash flows to find stocks trading below their true potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com